Research ExplorerPublicationsDoes obesity influence the prognosis of metastatic renal cel...

Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?

Standard

Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? / Steffens, Sandra; Grünwald, Viktor; Ringe, Kristina I; Seidel, Christoph; Eggers, Hendrik; Schrader, Mark; Wacker, Frank; Kuczyk, Markus A; Schrader, Andres J.

In: ONCOLOGIST, Vol. 16, No. 11, 2011, p. 1565-71.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Steffens, S, Grünwald, V, Ringe, KI, Seidel, C, Eggers, H, Schrader, M, Wacker, F, Kuczyk, MA & Schrader, AJ 2011, 'Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?', ONCOLOGIST, vol. 16, no. 11, pp. 1565-71. https://doi.org/10.1634/theoncologist.2011-0213

APA

Steffens, S., Grünwald, V., Ringe, K. I., Seidel, C., Eggers, H., Schrader, M., Wacker, F., Kuczyk, M. A., & Schrader, A. J. (2011). Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? ONCOLOGIST, 16(11), 1565-71. https://doi.org/10.1634/theoncologist.2011-0213

Vancouver

Steffens S, Grünwald V, Ringe KI, Seidel C, Eggers H, Schrader M et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? ONCOLOGIST. 2011;16(11):1565-71. https://doi.org/10.1634/theoncologist.2011-0213

Bibtex

@article{f433376047f249c580e63d55bce5466e,
title = "Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?",
abstract = "BACKGROUND: Obesity increases the risk for renal cell carcinoma (RCC). However, it has only recently been identified as an independent positive prognostic factor for localized RCC.OBJECTIVE: To determine whether obesity influences long-term prognosis in metastatic RCC patients receiving vascular endothelial growth factor-targeted therapy.DESIGN, SETTING, AND PARTICIPANTS: In 116 patients with metastatic RCC who received antiangiogenic agents (sunitinib, sorafenib, axitinib, bevacizumab) in 2005-2010, we evaluated whether body mass index (BMI), a body surface area (BSA) above the European average, the visceral fat area (VFA), or s.c. fat area (SFA) were of predictive relevance.MEASUREMENTS: BMI was categorized based on current World Health Organization definitions. BSA was stratified according to the European average for men (1.98 m(2)) and women (1.74 m(2)). VFA and SFA were dichotomized using the median of the observed distribution as the cutoff. The primary endpoints of this study were time to progression and overall survival time.RESULTS AND LIMITATIONS: The whole population had median progression-free and overall survival times of 8.3 months and 20.5 months, respectively. In contrast to BMI and BSA, higher than average VFA and SFA levels were significant predictors of longer progression-free and overall survival times. The major limitations of this study are its retrospective design and its heterogeneous patient population.CONCLUSION: This is the first study to identify high VFA and SFA levels as positive predictive biomarkers for patients who receive first-line antiangiogenic agents for metastatic RCC.",
keywords = "Angiogenesis Inhibitors, Body Mass Index, Body Surface Area, Carcinoma, Renal Cell, Disease-Free Survival, Female, Humans, Intra-Abdominal Fat, Kidney Neoplasms, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Obesity, Prognosis, Protein Kinase Inhibitors, Retrospective Studies, Risk Factors, Survival Analysis, Vascular Endothelial Growth Factor A",
author = "Sandra Steffens and Viktor Gr{\"u}nwald and Ringe, {Kristina I} and Christoph Seidel and Hendrik Eggers and Mark Schrader and Frank Wacker and Kuczyk, {Markus A} and Schrader, {Andres J}",
year = "2011",
doi = "10.1634/theoncologist.2011-0213",
language = "English",
volume = "16",
pages = "1565--71",
journal = "ONCOLOGIST",
issn = "1083-7159",
publisher = "ALPHAMED PRESS",
number = "11",

}

RIS

TY - JOUR

T1 - Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?

AU - Steffens, Sandra

AU - Grünwald, Viktor

AU - Ringe, Kristina I

AU - Seidel, Christoph

AU - Eggers, Hendrik

AU - Schrader, Mark

AU - Wacker, Frank

AU - Kuczyk, Markus A

AU - Schrader, Andres J

PY - 2011

Y1 - 2011

N2 - BACKGROUND: Obesity increases the risk for renal cell carcinoma (RCC). However, it has only recently been identified as an independent positive prognostic factor for localized RCC.OBJECTIVE: To determine whether obesity influences long-term prognosis in metastatic RCC patients receiving vascular endothelial growth factor-targeted therapy.DESIGN, SETTING, AND PARTICIPANTS: In 116 patients with metastatic RCC who received antiangiogenic agents (sunitinib, sorafenib, axitinib, bevacizumab) in 2005-2010, we evaluated whether body mass index (BMI), a body surface area (BSA) above the European average, the visceral fat area (VFA), or s.c. fat area (SFA) were of predictive relevance.MEASUREMENTS: BMI was categorized based on current World Health Organization definitions. BSA was stratified according to the European average for men (1.98 m(2)) and women (1.74 m(2)). VFA and SFA were dichotomized using the median of the observed distribution as the cutoff. The primary endpoints of this study were time to progression and overall survival time.RESULTS AND LIMITATIONS: The whole population had median progression-free and overall survival times of 8.3 months and 20.5 months, respectively. In contrast to BMI and BSA, higher than average VFA and SFA levels were significant predictors of longer progression-free and overall survival times. The major limitations of this study are its retrospective design and its heterogeneous patient population.CONCLUSION: This is the first study to identify high VFA and SFA levels as positive predictive biomarkers for patients who receive first-line antiangiogenic agents for metastatic RCC.

AB - BACKGROUND: Obesity increases the risk for renal cell carcinoma (RCC). However, it has only recently been identified as an independent positive prognostic factor for localized RCC.OBJECTIVE: To determine whether obesity influences long-term prognosis in metastatic RCC patients receiving vascular endothelial growth factor-targeted therapy.DESIGN, SETTING, AND PARTICIPANTS: In 116 patients with metastatic RCC who received antiangiogenic agents (sunitinib, sorafenib, axitinib, bevacizumab) in 2005-2010, we evaluated whether body mass index (BMI), a body surface area (BSA) above the European average, the visceral fat area (VFA), or s.c. fat area (SFA) were of predictive relevance.MEASUREMENTS: BMI was categorized based on current World Health Organization definitions. BSA was stratified according to the European average for men (1.98 m(2)) and women (1.74 m(2)). VFA and SFA were dichotomized using the median of the observed distribution as the cutoff. The primary endpoints of this study were time to progression and overall survival time.RESULTS AND LIMITATIONS: The whole population had median progression-free and overall survival times of 8.3 months and 20.5 months, respectively. In contrast to BMI and BSA, higher than average VFA and SFA levels were significant predictors of longer progression-free and overall survival times. The major limitations of this study are its retrospective design and its heterogeneous patient population.CONCLUSION: This is the first study to identify high VFA and SFA levels as positive predictive biomarkers for patients who receive first-line antiangiogenic agents for metastatic RCC.

KW - Angiogenesis Inhibitors

KW - Body Mass Index

KW - Body Surface Area

KW - Carcinoma, Renal Cell

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Intra-Abdominal Fat

KW - Kidney Neoplasms

KW - Male

KW - Middle Aged

KW - Molecular Targeted Therapy

KW - Neoplasm Metastasis

KW - Obesity

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Retrospective Studies

KW - Risk Factors

KW - Survival Analysis

KW - Vascular Endothelial Growth Factor A

U2 - 10.1634/theoncologist.2011-0213

DO - 10.1634/theoncologist.2011-0213

M3 - SCORING: Journal article

C2 - 22020210

VL - 16

SP - 1565

EP - 1571

JO - ONCOLOGIST

JF - ONCOLOGIST

SN - 1083-7159

IS - 11

ER -